VIATRIS INC. for VIATRIS INC
What was lobbied
5 issue areas, each in the filer's own words, with who lobbied on it and where.
Budget/Appropriations BUD
Medicaid Rebate provision of the Bipartisan Budget Act of 2015
Foreign entity interest: As the parent entities of Mylan Inc., Mylan NV and Mylan Holdings Limited have a general interest in the issues above.
| Lobbyist | Covered position, as disclosed |
|---|---|
| AKSHAI DATTA | — |
| KATHARINE HAYES | — |
| DAVID MARIN | — |
| PETER WALLACE | — |
| ANNE WILSON | — |
Trade (domestic/foreign) TRD
Trade issues related to generic medicines Access to global pharmaceutical supply chain
Foreign entity interest: As the parent entities of Mylan Inc., Mylan NV and Mylan Holdings Limited have a general interest in the issues above.
| Lobbyist | Covered position, as disclosed |
|---|---|
| AKSHAI DATTA | — |
| KATHARINE HAYES | — |
| DAVID MARIN | — |
| PETER WALLACE | — |
Financial Institutions/Investments/Securities FIN
Policy and oversight related to proxy advisory firms
Foreign entity interest: As the parent entities of Mylan Inc., Mylan NV and Mylan Holdings Limited have a general interest in the issues above.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID MARIN | — |
Copyright/Patent/Trademark CPT
Issues related Inter Partes Review (IPR) process for biosimilars and generic drugs S.344, H.R. 990 - Hatch-Waxman Integrity Act of 2019 Patent Settlements
Foreign entity interest: As the parent entities of Mylan Inc., Mylan NV and Mylan Holdings Limited have a general interest in the issues above.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID MARIN | — |
| PETER WALLACE | — |
Health Issues HCR
Drug pricing issues, access to generic medicines, Medicare Part D program and generic drugs Generic drug quality and FDA oversight Medicare reimbursement for biosimilars, shared savings for Part B providers S.2543, Prescription Drug Pricing Reduction Act S. 1416, Affordable Prescriptions for Patients Act S. 1895 Lower Health Care Costs Act of 2019 H.R. 3- Lower Drug Costs Now Act of 2019 H.R. 938 - BLOCKING Act of 2019 H.R. 1499 - The Protecting Consumer Access to Generic Drugs Act of 2019 Part D Formulary Design and Generic Drug Tiering H.R. 4913 - Ensuring Access to Lower-Cost Medicines for Seniors Act H.R. 4455 - BIOSIM Act H.R. 4629 - Star Rating for Biosimilars Act H.R. 6179 - Increasing Access to Biosimilars Act of 2020 S. 2723 - Mitigating Emergency Drug Shortages Act H.R. 5304 - PBM Transparency in Prescription Drug Costs Act H.R. 748 - CARES Act
Foreign entity interest: As the parent entities of Mylan Inc., Mylan NV and Mylan Holdings Limited have a general interest in the issues above.
| Lobbyist | Covered position, as disclosed |
|---|---|
| AKSHAI DATTA | — |
| KATHARINE HAYES | — |
| DAVID MARIN | — |
| PETER WALLACE | — |
| ANNE WILSON | — |
Foreign entities
Foreign owners and affiliates the filer disclosed. Amounts are as declared on this filing.
| Entity | Country | Principal place of business | Ownership | Contribution declared |
|---|---|---|---|---|
| MYLAN NV | United Kingdom | United Kingdom | 100.0% | — |
| MYLAN HOLDINGS LIMITED | United Kingdom | United Kingdom | 100.0% | — |
Support LegiList
This page is free, carries no paywall, and is built and maintained by one person. If the record here is useful to you, a few dollars keeps it going.
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.